<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163138">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912196</url>
  </required_header>
  <id_info>
    <org_study_id>MSI-CP.002</org_study_id>
    <nct_id>NCT01912196</nct_id>
  </id_info>
  <brief_title>Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized Add-On Study of MSI-195 (Methylation Sciences Inc. S-Adenosyl-L-Methionine, SAMe) For Patients With Major Depressive Disorder(MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MSI Methylation Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MSI Methylation Sciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of 800 mg MSI-195 in
      reducing symptoms of depression in Major Depressive Disorder (MDD)patients with inadequate
      response to current antidepressant therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in the total Hamilton Depression Rating Scale (HAM-D17)  between randomization and end of study.</measure>
    <time_frame>assessed from baseline to week 8 (end of study)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on historical data, the standard deviation is assumed to range between 9 and 12.  With a standard effect size of 0.367 a total of at least 120 evaluable patients per group are needed to provide 80% power with a two-sided 5% significance level. HAM-D17 will be derived from the Combined HAM-D28-MADRS Instrument.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in the total score of the Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>collected at baseline, weeks 2, 4, 6, 7 and 8 (end of study)</time_frame>
    <safety_issue>No</safety_issue>
    <description>for the MADRS, the number and proportion of patients who are responders at the end of the study and the number and proportion of patients who are in remission at the end of the study will be summarized by treatment group, along with the difference and 95% confidence interval for the difference (based on the Wilson Score method).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total score of the Clinical Global Impression Improvement Scale (CGI-S)</measure>
    <time_frame>assessed from baseline, weeks 2, 4, 7 and 8 (end of study)</time_frame>
    <safety_issue>No</safety_issue>
    <description>the number and proportion of patients who are responders at the end of the study and the number and proportion of patients who are in remission at the end of the study will be summarized by treatment group, along with the difference and 95% confidence interval for the difference (based on the Wilson Score method). Remission is defined as a score of 1 or 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from randomization to each study visit in the total score of the Inventory of Depressive Symptomatology-Self Rated (IDS-SR30)</measure>
    <time_frame>assessed on baseline visit, Week 2, 4, 6, and 8 (end of study).</time_frame>
    <safety_issue>No</safety_issue>
    <description>A response is defined as a reduction in the IDS-SR30 score of ≥50% and remission is defined as a score of ≤14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>collected at baseline, weeks 1, 2, 3, 4, 6, 8 and 9 (follow up)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>collected from signing informed consent through 7 days after the last dose of study treatment. Ascertained by qualified clinician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>assessed at baseline, weeks 2, 4, 6 and 8 (end of study)</time_frame>
    <safety_issue>No</safety_issue>
    <description>administered by qualified clinician</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Major Depressive Disorder (MDD)</condition>
  <arm_group>
    <arm_group_label>MSI-195</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the MSI-195 arm will receive treatment with 2 tablets (800 mg) of MSI-195 plus on-going antidepressant therapy (ADT).
MSI-195 800 mg (two tablets)  taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to the placebo arm will receive 2 tablets placebo plus on-going antidepressant therapy (ADT).
Placebo (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSI-195</intervention_name>
    <arm_group_label>MSI-195</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets the Diagnostic and Statistical Manual of Mental Disorder, 4th Edition, Text
             Revision (DSM-IV-TR) criteria for Major Depressive Disorder (MDD)

          -  A total score of 16 or higher on the Hamilton Rating Scale for Depression- 17 item
             version (HAM-D17) at the Screening and Baseline Visits, with a score of ≥2 on mood
             item 1.

          -  Have experienced 1-4 prior Major Depressive Episodes. Patients with more than 5
             lifetime episodes (including current episode) will require discussion with the
             medical monitor prior to inclusion.

          -  Failed 1-3 treatment regimens in the current depressive episode

          -  Received an adequate dose and duration of Antidepressant Therapy (ADT) (on ADT for at
             least 6 weeks with a stable dose for at least 3 weeks)

        Exclusion Criteria:

          -  Failed 4 or more adequate treatment regimens in current episode of depression

          -  patient may have a significant risk for suicidal behavior during the course of their
             participation in the study

          -  Intolerance to SAMe; Prior use of MSI-195

          -  History of any of the following psychiatric disorders: eating disorder within 6
             months; obsessive compulsive disorder, psychotic disorder, bipolar disorder, mental
             retardation, dementia or other forms of cognitive impairment at any time or alcohol
             or substance abuse

          -  &gt;3X upper limit of normal (ULN) Alkaline Phosphatase, aspartate aminotransferase
             (AST), alanine aminotransferase (ALT); &gt;1.5X ULN total bilirubin

          -  Pregnant or lactating women

          -  Any history of seizures, excluding febrile seizures

          -  Known positivity for human immunodeficiency virus
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clayton Janik, CTM</last_name>
    <phone>512-747-5639</phone>
    <email>Clayton.Janik@ppdi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Smith, PM</last_name>
    <phone>512-913-6731</phone>
    <email>scott.smith@ppdi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Bell</last_name>
      <phone>205-823-0766</phone>
      <email>cbellbrg@bellsouth.net</email>
    </contact>
    <investigator>
      <last_name>William Patterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Morrissey</last_name>
      <phone>818-705-7450</phone>
      <email>jmorrissey@priresearch.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Grosz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lily Le</last_name>
      <phone>714-799-7799</phone>
      <email>lilyle@cnstrial.com</email>
    </contact>
    <investigator>
      <last_name>David Walling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Henry</last_name>
      <phone>714-827-3667</phone>
      <email>mhenry@priresearch.com</email>
    </contact>
    <investigator>
      <last_name>Nader Oskooilar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Fosteson</last_name>
      <phone>310-208-7144</phone>
      <email>cfosteson@pacificmedresearch.com</email>
    </contact>
    <investigator>
      <last_name>Robert Gerner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marci Smith</last_name>
      <phone>619-327-0155</phone>
      <email>smithm@synergysandiego.com</email>
    </contact>
    <investigator>
      <last_name>Mohammed Bari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>My Linh Tong</last_name>
      <phone>949-752-7910</phone>
      <email>mtong@priresearch.com</email>
    </contact>
    <investigator>
      <last_name>Don DeFrancisco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Cote</last_name>
      <phone>877-602-5777</phone>
      <email>shawnacote@pacifictrials.com</email>
    </contact>
    <investigator>
      <last_name>Ira Glick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Worsley Carmalee</last_name>
      <phone>760-758-2222</phone>
      <email>cworsley@excellresearch.com</email>
    </contact>
    <investigator>
      <last_name>Sherry Soefje, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aruna Parikh</last_name>
      <phone>310-523-4200</phone>
      <email>arunaparikh@cnstrial.com</email>
    </contact>
    <investigator>
      <last_name>Armen Goenjian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Angel</last_name>
      <phone>904-281-5757</phone>
      <email>sangel@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Mark Joyce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI INvestigational Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cary Carrion</last_name>
      <phone>407-483-0989</phone>
      <email>ccarrion@accuratect.com</email>
    </contact>
    <investigator>
      <last_name>Rosario Hidalgo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Martin</last_name>
      <phone>407-425-5100</phone>
      <email>smartin@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Linda Harper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Kolin</last_name>
      <phone>407-644-1122</phone>
      <email>Karen@kolinresearchgroup.com</email>
    </contact>
    <investigator>
      <last_name>Irving Kolin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon Lenfest</last_name>
      <phone>770-817-9200</phone>
      <email>crc4@atlanta-institute.com</email>
    </contact>
    <investigator>
      <last_name>Angelo Sambunaris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Schmidt</last_name>
      <phone>847-230-3599</phone>
      <email>karen.schmidt@alexian.net</email>
    </contact>
    <investigator>
      <last_name>Mark Lerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21285</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Sklar</last_name>
      <phone>410-938-3136</phone>
      <email>jsklar@sheppardpratt.org</email>
    </contact>
    <investigator>
      <last_name>Scott Aaronson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Flowood</city>
        <state>Missouri</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Richardson</last_name>
      <phone>6014205810</phone>
      <email>krichardson@precise-research.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Kwentus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmine Davis</last_name>
      <phone>702-527-7401</phone>
      <email>jdavis@altearesearch.com</email>
    </contact>
    <investigator>
      <last_name>Jelena Kunovac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Ridolfi</last_name>
      <phone>856-334-6062</phone>
      <email>eridolfi@CRILifetree.com</email>
    </contact>
    <investigator>
      <last_name>David Krefetz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Divya Nair</last_name>
      <phone>505-848-3773</phone>
      <email>divya@albneuro.com</email>
    </contact>
    <investigator>
      <last_name>Glenn Michael Dempsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Johnson</last_name>
      <phone>212-595-5012</phone>
      <email>AJohnson@MedicalResearchNetwork.com</email>
    </contact>
    <investigator>
      <last_name>Michael Liebowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Castillo</last_name>
      <phone>585-241-9670</phone>
      <email>scastillo@flclinical.com</email>
    </contact>
    <investigator>
      <last_name>Sarah Atkinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Blackford</last_name>
      <phone>330-493-1118</phone>
      <email>cblackford@nb-cr.com</email>
    </contact>
    <investigator>
      <last_name>Shishuka Malhotra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Sarvis</last_name>
      <phone>937-424-1050</phone>
      <email>ASarvis@midwestclinical.com</email>
    </contact>
    <investigator>
      <last_name>Bernadette D'Souza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika Truitt</last_name>
      <phone>503-972-9822</phone>
      <email>atruitt@summitnetwork.com</email>
    </contact>
    <investigator>
      <last_name>Alan Yeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Iskiwitz</last_name>
      <phone>901-843-1045</phone>
      <email>kiskiwitz@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Valerie Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Pallatto Hughan</last_name>
      <phone>512-380-9925</phone>
      <email>coreyph@fstrials.com</email>
    </contact>
    <investigator>
      <last_name>Donald Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Gardner</last_name>
      <phone>512-323-2622</phone>
      <email>kat.gardner@communityclinical.com</email>
    </contact>
    <investigator>
      <last_name>David Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Dolan</last_name>
      <phone>214-369-2600</phone>
      <email>stephanied@fstrials.com</email>
    </contact>
    <investigator>
      <last_name>Michael Downing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Timmons</last_name>
      <phone>713-527-8448</phone>
      <email>jtimmons@houstonclintrials.com</email>
    </contact>
    <investigator>
      <last_name>Alain Katic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janna Espinosa</last_name>
      <phone>801-261-8930</phone>
      <email>jannaespinosa@radiantresearch.com</email>
    </contact>
    <investigator>
      <last_name>Mark Johnston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSI Investigational Site</name>
      <address>
        <city>Brown Deer</city>
        <state>Wisconsin</state>
        <zip>53223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Simon</last_name>
      <phone>414-357-9444</phone>
      <email>mollymsimon@aol.com</email>
    </contact>
    <investigator>
      <last_name>Jeff Simon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>July 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depressive Disorder</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
